MCID: CLN015
MIFTS: 57

Colon Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colon Adenocarcinoma

MalaCards integrated aliases for Colon Adenocarcinoma:

Name: Colon Adenocarcinoma 12 13 55 15
Adenocarcinoma of the Colon 12 6
Adenocarcinoma of Colon 12 73
Colonic Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:234
NCIt 50 C4349
UMLS 73 C0338106

Summaries for Colon Adenocarcinoma

Disease Ontology : 12 A colon carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colon Adenocarcinoma, also known as adenocarcinoma of the colon, is related to adenocarcinoma and adenoma. An important gene associated with Colon Adenocarcinoma is RAD54L (RAD54 Like), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Benzocaine and Zinc have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and testes, and related phenotypes are cellular and endocrine/exocrine gland

Wikipedia : 76 Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from... more...

Related Diseases for Colon Adenocarcinoma

Diseases related to Colon Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 32.2 APC CDH1 CTNNB1 MLH1 PTGS2
2 adenoma 30.5 APC CTNNB1 MLH1 ODC1 PTGS2
3 colitis 30.3 ABCB1 CTNNB1 MLH1 PTGS2
4 cholangiocarcinoma 30.1 PTGS2 KRT20 CTNNB1 CEACAM5 CDH1 APC
5 lung cancer susceptibility 3 30.1 PTGS2 NQO1 KRT20 CTNNB1 CEACAM5 CDH1
6 transitional cell carcinoma 30.0 CDH1 KRT20 PTGS2
7 mismatch repair cancer syndrome 29.6 APC CTNNB1 MLH1 MSH6
8 hepatocellular carcinoma 29.5 CTNNB1 CEACAM5 CDH1 CASP3 BAX APC
9 lynch syndrome 29.5 APC CTNNB1 MLH1 MSH6
10 colorectal adenocarcinoma 29.4 PTGS2 MSH6 MLH1 KRT20 CTNNB1 CEACAM5
11 familial adenomatous polyposis 29.3 PTGS2 ODC1 MSH6 MLH1 CTNNB1 CDH1
12 ovarian cancer 29.3 ABCB1 BAX CASP3 CDH1 CTNNB1 MLH1
13 breast cancer 28.9 TYMS RAD54L PTGS2 ODC1 NQO1 MSH6
14 keratosis palmoplantaris adenocarcinoma of the colon 12.3
15 submucosal invasive colon adenocarcinoma 12.2
16 colon mucinous adenocarcinoma 11.6
17 gastrointestinal carcinoma 10.4 ABCB1 KRT20 TYMS
18 desmoid disease, hereditary 10.3 APC CTNNB1
19 large intestine adenocarcinoma 10.3 CDH1 CTNNB1 KRT20
20 goblet cell carcinoid 10.3 CDH1 CTNNB1 KRT20
21 esophageal adenosquamous carcinoma 10.3 CDH1 CEACAM5
22 polyposis syndrome, hereditary mixed, 1 10.3 APC MLH1 PTGS2
23 lower lip cancer 10.3 CASP3 MLH1
24 linitis plastica 10.3 CDH1 KRT20
25 colonic benign neoplasm 10.3 CEACAM5 CTNNB1 PTGS2
26 nasopharyngeal disease 10.3 CASP3 CDH1 CTNNB1
27 oral cancer 10.3 CASP3 CDH1 PTGS2
28 infiltrative basal cell carcinoma 10.3 CDH1 CEACAM5 KRT20
29 pharynx cancer 10.3 CASP3 CDH1 CTNNB1
30 lung acinar adenocarcinoma 10.3 CTNNB1 KRT20
31 cervix disease 10.3 CASP3 CDH1 CTNNB1
32 familial adenomatous polyposis 1 10.3 APC CTNNB1
33 gastrointestinal system benign neoplasm 10.3 CEACAM5 CTNNB1 PTGS2
34 euryblepharon 10.3 CDH1 CTNND1
35 anaplastic thyroid cancer 10.3 CASP3 CDH1 CTNNB1
36 male reproductive organ cancer 10.3 CASP3 CDH1 CTNNB1
37 tongue cancer 10.3 CASP3 CDH1 CTNNB1
38 intrahepatic cholangiocarcinoma 10.3 CDH1 CTNNB1 KRT20
39 uterine carcinosarcoma 10.3 CDH1 CTNNB1 PTGS2
40 barrett esophagus 10.3 APC KRT20 ODC1 PTGS2
41 lymphoma, non-hodgkin, familial 10.3 ABCB1 BAX CASP3 RAD54L
42 familial colorectal cancer 10.3 APC CDH1 MLH1
43 breast ductal carcinoma 10.3 CDH1 CTNNB1 RAD54L
44 cell type benign neoplasm 10.3 CEACAM5 CTNNB1 MLH1
45 rectal neoplasm 10.3 CEACAM5 KRT20 MLH1 TYMS
46 hematologic cancer 10.3 ABCB1 BAX CASP3 MLH1
47 hepatoblastoma 10.3 ABCB1 APC CASP3 CTNNB1
48 tongue squamous cell carcinoma 10.3 CASP3 CDH1 CTNNB1
49 fibroepithelial basal cell carcinoma 10.3 CEACAM5 KRT20
50 adenoid squamous cell carcinoma 10.3 CDH1 KRT20

Graphical network of the top 20 diseases related to Colon Adenocarcinoma:



Diseases related to Colon Adenocarcinoma

Symptoms & Phenotypes for Colon Adenocarcinoma

MGI Mouse Phenotypes related to Colon Adenocarcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 APC BAX CASP3 CDH1 CTNNB1 CTNND1
2 endocrine/exocrine gland MP:0005379 10.16 ABCB1 ACSL4 APC BAX CASP3 CDH1
3 homeostasis/metabolism MP:0005376 10.15 ABCB1 ACSL4 APC BAX CASP3 CDH1
4 hematopoietic system MP:0005397 10.14 ABCB1 ACSL4 APC BAX CASP3 CTNNB1
5 digestive/alimentary MP:0005381 10.08 ABCB1 APC CASP3 CDH1 CTNNB1 CTNND1
6 immune system MP:0005387 10.06 ABCB1 APC BAX CASP3 CDH1 CTNNB1
7 mortality/aging MP:0010768 9.97 ABCB1 ACSL4 APC BAX CASP3 CDH1
8 hearing/vestibular/ear MP:0005377 9.91 ABCB1 ACSL4 APC BAX CASP3 CTNNB1
9 integument MP:0010771 9.91 APC CASP3 CDH1 CTNNB1 CTNND1 MLH1
10 neoplasm MP:0002006 9.61 APC BAX CDH1 CTNNB1 CTNND1 MLH1
11 reproductive system MP:0005389 9.28 ABCB1 ACSL4 APC BAX CASP3 CDH1

Drugs & Therapeutics for Colon Adenocarcinoma

Drugs for Colon Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 213)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
2
Zinc Approved, Investigational Phase 4 7440-66-6
3 tannic acid Approved Phase 4
4 Hypoglycemic Agents Phase 4
5 Insulin, Globin Zinc Phase 4
6 insulin Phase 4
7
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 68538-85-2
8
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
9
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
10
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
11
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
12
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
13
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
14
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
15
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
16
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2 22916-47-8 4189
17
Raltitrexed Approved, Investigational Phase 3,Phase 2 112887-68-0 104758
18
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
19
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
20
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
21
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
22
Tegafur Approved, Investigational Phase 3,Phase 2 17902-23-7 5386
23
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
24
Floxuridine Approved Phase 3,Phase 2,Phase 1 50-91-9 5790
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
26
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
27
Dalteparin Approved Phase 3 9005-49-6
28
Tinzaparin Approved Phase 3 9005-49-6, 9041-08-1 25244225
29
Atezolizumab Approved, Investigational Phase 3 1380723-44-3
30
Aspirin Approved, Vet_approved Phase 3 50-78-2 2244
31
Promethazine Approved, Investigational Phase 3 60-87-7 4927
32
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
33
Diphenhydramine Approved, Investigational Phase 3 147-24-0, 58-73-1 3100
34
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
35
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
36
Doxil Approved June 1999 Phase 3,Phase 2 31703
37
Vatalanib Investigational Phase 3 212141-54-3 151194
38
Eniluracil Investigational Phase 3 59989-18-3
39 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
40 Protective Agents Phase 3,Phase 2,Phase 1
41 Folate Phase 3,Phase 2,Phase 1
42 Calcium, Dietary Phase 3,Phase 2,Phase 1,Not Applicable
43 Vitamin B9 Phase 3,Phase 2,Phase 1
44 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
45 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
46 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
47 Immunologic Factors Phase 3,Phase 2,Phase 1,Early Phase 1
48 Alkylating Agents Phase 3,Phase 2,Phase 1
49 Antibiotics, Antitubercular Phase 3,Phase 2
50 Micronutrients Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 266)
# Name Status NCT ID Phase Drugs
1 Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial Not yet recruiting NCT02746432 Phase 4 Hyper insulinemic euglycemic clamp
2 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
3 Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer Unknown status NCT00958737 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin;XELOX regimen;Capecitabine
4 Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Unknown status NCT00091312 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
5 Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer Unknown status NCT00005979 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
6 Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00182715 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
7 Combination Chemotherapy in Treating Patients With Colon Cancer Unknown status NCT00046995 Phase 3 carboplatin;fluorouracil;leucovorin calcium
8 Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00070213 Phase 3 FOLFOX regimen;capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
9 Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil Unknown status NCT00389870 Phase 3 cyclosporine;irinotecan hydrochloride
10 Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Unknown status NCT00274872 Phase 2, Phase 3 fluorouracil;leucovorin calcium;oxaliplatin
11 Combination Chemotherapy in Treating Patients With Recurrent Metastatic Colorectal Cancer Unknown status NCT00003260 Phase 3 FOLFIRI regimen;FOLFOX regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
12 Combination Chemotherapy With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00021281 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;semaxanib
13 Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00008281 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
14 Comparing Two Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00006468 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
15 Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer Unknown status NCT00482222 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
16 Intravenous Compared With Intrahepatic Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver Unknown status NCT00002692 Phase 3 fluorouracil;isolated perfusion;leucovorin calcium
17 Palliative Chemotherapy in Treating Patients With Advanced Colorectal Cancer Unknown status NCT00002893 Phase 3 fluorouracil;leucovorin calcium;raltitrexed
18 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
19 Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery Completed NCT00427310 Phase 3 fluorouracil;sodium heparin
20 Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver Completed NCT00023868 Phase 3 FOLFIRI regimen;cisplatin;doxorubicin hydrochloride;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C
21 Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00003594 Phase 3 irinotecan;fluorouracil;leucovorin calcium;oxaliplatin
22 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer Completed NCT00056446 Phase 3 Vatalanib
23 Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. Completed NCT00056459 Phase 3 Vatalanib
24 Combination Chemotherapy in Treating Patients With Stage III Colon Cancer Completed NCT00003835 Phase 3 leucovorin calcium;fluorouracil;irinotecan hydrochloride
25 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed NCT00079274 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil;Locally Directed Therapy
26 Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery Completed NCT00660894 Phase 3 folinate calcium;tegafur-uracil;tegafur-gimeracil-oteracil potassium
27 Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon Completed NCT00085163 Phase 3 celecoxib;fluorouracil;leucovorin calcium
28 Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery Completed NCT00265811 Phase 3 Folfox + Cetuximab;Folfox
29 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
30 Combination Chemotherapy in Treating Patients With Resected Colon Cancer Completed NCT00378716 Phase 3 5-fluorouracil;leucovorin calcium;tegafur;uracil
31 Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer Completed NCT00064181 Phase 3 FOLFIRI regimen;capecitabine;celecoxib;fluorouracil;irinotecan hydrochloride;leucovorin calcium
32 Tegafur-Uracil or Observation in Treating Patients With Stage II Colorectal Cancer That Has Been Completely Removed By Surgery Completed NCT00392899 Phase 3 UFT adjuvant chemotherapy
33 Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients Following Surgery for Stage III Colorectal Cancer Completed NCT00026273 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
34 Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer Completed NCT00002575 Phase 3
35 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
36 Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer Completed NCT00003873 Phase 3 fluorouracil;eniluracil
37 Combination Chemotherapy in Treating Patients With Colorectal Cancer and Resectable Metastases Completed NCT00268398 Phase 3 oxaliplatin, folinic acid, fluorouracil;oxaliplatin, irinotecan, folinic acid, fluorouracil
38 Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM) Completed NCT00265824 Phase 3 bevacizumab;bevacizumab, erlotinib
39 Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer Completed NCT00004252 Phase 3 fluorouracil;leucovorin calcium;semaxanib
40 Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer Completed NCT00096278 Phase 3 oxaliplatin;leucovorin calcium;fluorouracil
41 Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated Completed NCT00025337 Phase 3 oxaliplatin;leucovorin calcium;fluorouracil
42 Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer Completed NCT00062426 Phase 3 capecitabine;fluorouracil;leucovorin calcium;oxaliplatin
43 Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery Completed NCT00303771 Phase 3 fluorouracil;irinotecan hydrochloride;leucovorin calcium
44 PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study Completed NCT00911170 Phase 3 Pegfilgrastim;Placebo;Standard Chemotherapy
45 Fluorouracil and Leucovorin With or Without Irinotecan in Treating Patients With Metastatic Colorectal Cancer Completed NCT00004885 Phase 3 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
46 Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer Completed NCT00003287 Phase 3 FOLFOX regimen;fluorouracil;leucovorin calcium;oxaliplatin
47 Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer Completed NCT00008060 Phase 3 FOLFIRI regimen;FOLFOX regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
48 Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer Completed NCT00975897 Phase 2, Phase 3 fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
49 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery Completed NCT00316914 Phase 3 calcium gluconate;magnesium sulfate
50 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed NCT01099449 Phase 3 calcium gluconate;magnesium sulfate;oxaliplatin

Search NIH Clinical Center for Colon Adenocarcinoma

Genetic Tests for Colon Adenocarcinoma

Anatomical Context for Colon Adenocarcinoma

MalaCards organs/tissues related to Colon Adenocarcinoma:

41
Colon, Liver, Testes, T Cells, Lung, Lymph Node, Breast

Publications for Colon Adenocarcinoma

Articles related to Colon Adenocarcinoma:

(show top 50) (show all 1241)
# Title Authors Year
1
miR-223-RhoB signaling pathway regulates the proliferation and apoptosis of colon adenocarcinoma. ( 29660302 )
2018
2
Hsa-miR-370 inhibited P-selectin-induced cell adhesion in human colon adenocarcinoma cells. ( 29922946 )
2018
3
Minimally invasive surgery for stage III colon adenocarcinoma is associated with less delay to initiation of adjuvant systemic therapy and improved survival. ( 29967992 )
2018
4
Transforming Growth Factor Beta 2 Inhibits Growth and Proliferation Potential of Smad4 and p53 Mutated Human Colon Adenocarcinoma Cells. ( 29948613 )
2018
5
A rare case of ascending colon adenocarcinoma incarcerated in an inguinoscrotal hernia: case report and literature review. ( 29785528 )
2018
6
Vaccination with human amniotic epithelial cells confer effective protection in a murine model of Colon adenocarcinoma. ( 29139122 )
2018
7
Expression of Hippo pathway genes and their clinical significance in colon adenocarcinoma. ( 29541248 )
2018
8
<i>De novo</i> expression of human polypeptide<i>N</i>-acetylgalactosaminyltransferase 6 (GalNAc-T6) in colon adenocarcinoma inhibits the differentiation of colonic epithelium. ( 29187600 )
2018
9
Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation. ( 29289836 )
2018
10
Curcumin induces apoptosis and cell cycle arrest via the activation of reactive oxygen species-independent mitochondrial apoptotic pathway in Smad4 and p53 mutated colon adenocarcinoma HT29 cells. ( 29673545 )
2018
11
A rare case of oral metastasis of colon adenocarcinoma. ( 29475082 )
2018
12
G protein-coupled receptor LGR6 is an independent risk factor for colon adenocarcinoma. ( 29971639 )
2018
13
Comprehensive analysis of differential expression profiles of mRNAs and lncRNAs and identification of a 14-lncRNA prognostic signature for patients with colon adenocarcinoma. ( 29565464 )
2018
14
Colon adenocarcinoma presenting a Plummer-Vinson Syndrome. ( 29885869 )
2018
15
Co-expression Network Analysis Identified COL8A1 Is Associated with the Progression and Prognosis in Human Colon Adenocarcinoma. ( 29497907 )
2018
16
Phalangeal metastasis in colon adenocarcinoma. ( 29807858 )
2018
17
A 65a89gene signature for prognostic prediction in colon adenocarcinoma. ( 29393333 )
2018
18
A rare case of <i>Clostridium septicum</i> aortitis with colon adenocarcinoma. ( 29707691 )
2018
19
Two subsequent metachronous diseases: Granuloma annulare and colon adenocarcinoma. ( 30539883 )
2018
20
Distinct prognostic value of dynactin subunit 4 (DCTN4) and diagnostic value of DCTN1, DCTN2, and DCTN4 in colon adenocarcinoma. ( 30510450 )
2018
21
Identification of prognostic miRNA biomarkers for predicting overall survival of colon adenocarcinoma and bioinformatics analysis: A study based on The Cancer Genome Atlas database. ( 30536901 )
2018
22
Pyruvate Treatment Restores the Effectiveness of Chemotherapeutic Agents in Human Colon Adenocarcinoma and Pleural Mesothelioma Cells. ( 30423827 )
2018
23
Identification of key lncRNAs in the carcinogenesis and progression of colon adenocarcinoma by co-expression network analysis. ( 30430631 )
2018
24
Prognostic differences between lymphoepithelioma-like colon carcinoma and colon adenocarcinoma. ( 30449118 )
2018
25
Significance of PYK2 level as a prognosis predictor in patients with colon adenocarcinoma after surgical resection. ( 30464511 )
2018
26
Optimization of nimesulide-loaded Solid Lipid Nanoparticles (SLN) by factorial design, release profile and cytotoxicity in human colon adenocarcinoma cell line. ( 30477410 )
2018
27
E2F1-mediated MNX1-AS1-miR-218-5p-SEC61A1 feedback loop contributes to the progression of colon adenocarcinoma. ( 30362161 )
2018
28
Pharmacokinetic, Antiproliferative and Apoptotic Effects of Phenolic Acids in Human Colon Adenocarcinoma Cells Using In Vitro and In Silico Approaches. ( 30297681 )
2018
29
Cutaneous metastasis of colon adenocarcinoma. ( 30302429 )
2018
30
Pseudomyxoma pleurii and peritonei secondary to sigmoid colon adenocarcinoma: a rare clinico-pathologico-radiological presentation. ( 30250743 )
2018
31
Identification of long noncoding RNAs biomarkers for diagnosis and prognosis in patients with colon adenocarcinoma. ( 30269368 )
2018
32
MicroRNA-145 regulates the proliferation, migration and invasion of human primary colon adenocarcinoma cells by targeting MAPK1. ( 30272312 )
2018
33
Preparation of cupric sulfate-based self-emulsifiable nanocomposites and their application to the photothermal therapy of colon adenocarcinoma. ( 30208513 )
2018
34
Genome-wide methylation analysis identifies novel prognostic methylation markers in colon adenocarcinoma. ( 30223100 )
2018
35
Changes in spatio-temporal localization of tripeptidyl peptidase II (TPPII) in murine colon adenocarcinoma cells during aggresome formation: a microscopy study based on a novel fluorescent proteasome inhibitor. ( 30226264 )
2018
36
Analysis of lncRNA-Associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Colon Adenocarcinoma. ( 30231249 )
2018
37
A left-sided cystic pancreatic incidentaloma with sigmoid colon adenocarcinoma: a case report. ( 30157943 )
2018
38
Age is nothing but a number: radical en bloc resection of colon adenocarcinoma with abdominal wall reconstruction in an 81 year old. ( 30174823 )
2018
39
Expression and Localization of Cathepsins B, D and G in Cancer Stem Cells in Liver Metastasis From Colon Adenocarcinoma. ( 30177970 )
2018
40
Screening key long non-coding RNAs in early-stage colon adenocarcinoma by RNA-sequencing. ( 30182733 )
2018
41
Should adjuvant chemotherapy be recommended to a 75-year-old woman with deficient mismatch repair (dMMR) gene product expression seen in a stage II colon adenocarcinoma with lymphovascular invasion? ( 30119912 )
2018
42
Characterization of microRNA expression in primary human colon adenocarcinoma cells (SW480) and their lymph node metastatic derivatives (SW620). ( 30127618 )
2018
43
Overexpression of miR-21-5p promotes proliferation and invasion of colon adenocarcinoma cells through targeting CHL1. ( 30134821 )
2018
44
Hyperglycemia Promotes Chemoresistance Through the Reduction of the Mitochondrial DNA Damage, the Bax/Bcl-2 and Bax/Bcl-XL Ratio, and the Cells in Sub-G1 Phase Due to Antitumoral Drugs Induced-Cytotoxicity in Human Colon Adenocarcinoma Cells. ( 30150934 )
2018
45
Early stage clear cell adenocarcinoma of the colon examined in detail with image-enhanced endoscopy: a case report. ( 30062544 )
2018
46
Curcumin-entrapped MUC-1 aptamer targeted dendrimer-gold hybrid nanostructure as a theranostic system for colon adenocarcinoma. ( 30048777 )
2018
47
Sigmoid Colon Adenocarcinoma with Isolated Loss of PMS2 Presenting in a Patient with Synchronous Prostate Cancer with Intact MMR: Diagnosis and Analysis of the Family Pedigree. ( 30061258 )
2018
48
Genome‑scale analysis to identify potential prognostic microRNA biomarkers for predicting overall survival in patients with colon adenocarcinoma. ( 30066920 )
2018
49
A solitary cutaneous metastasis from colon adenocarcinoma: Dermoscopic and confocal microscopy features. ( 30073979 )
2018
50
Modified PAMAM vehicles for effective TRAIL gene delivery to colon adenocarcinoma: in vitro and in vivo evaluation. ( 30095012 )
2018

Variations for Colon Adenocarcinoma

ClinVar genetic disease variations for Colon Adenocarcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.3927_3931delAAAGA (p.Glu1309Aspfs) deletion Pathogenic rs121913224 GRCh37 Chromosome 5, 112175218: 112175222
2 APC NM_000038.5(APC): c.3927_3931delAAAGA (p.Glu1309Aspfs) deletion Pathogenic rs121913224 GRCh38 Chromosome 5, 112839521: 112839525
3 RAD54L NM_001142548.1(RAD54L): c.188C> A (p.Pro63His) single nucleotide variant Pathogenic rs121908688 GRCh37 Chromosome 1, 46715769: 46715769
4 RAD54L NM_001142548.1(RAD54L): c.188C> A (p.Pro63His) single nucleotide variant Pathogenic rs121908688 GRCh38 Chromosome 1, 46250097: 46250097
5 APC NM_000038.5(APC): c.7832C> T (p.Thr2611Ile) single nucleotide variant Uncertain significance rs587778037 GRCh37 Chromosome 5, 112179123: 112179123
6 APC NM_000038.5(APC): c.7832C> T (p.Thr2611Ile) single nucleotide variant Uncertain significance rs587778037 GRCh38 Chromosome 5, 112843426: 112843426
7 APC NM_001127511.2(APC): c.1409T> C (p.Leu470Pro) single nucleotide variant Uncertain significance rs368434773 GRCh37 Chromosome 5, 112162859: 112162859
8 APC NM_001127511.2(APC): c.1409T> C (p.Leu470Pro) single nucleotide variant Uncertain significance rs368434773 GRCh38 Chromosome 5, 112827162: 112827162
9 MSH6 NM_000179.2(MSH6): c.1805_1806insA (p.Glu604Glyfs) insertion Pathogenic GRCh37 Chromosome 2, 48026928: 48026928
10 MSH6 NM_000179.2(MSH6): c.1805_1806insA (p.Glu604Glyfs) insertion Pathogenic GRCh38 Chromosome 2, 47799788: 47799789

Cosmic variations for Colon Adenocarcinoma:

9 (show top 50) (show all 11136)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM33066 ZZZ3 large intestine,colon,carcinoma,NS c.1366C>T p.P456S 1:77631989-77631989 9
2 COSM6940205 ZRSR2 large intestine,colon,carcinoma,NS c.553G>T p.D185Y 23:15809314-15809314 9
3 COSM6452015 ZRSR2 large intestine,colon,carcinoma,NS c.917G>A p.R306Q 23:15820296-15820296 9
4 COSM33067 ZNHIT6 large intestine,colon,carcinoma,NS c.1364T>A p.L455H 1:85657855-85657855 9
5 COSM32824 ZNHIT1 large intestine,colon,carcinoma,NS c.400C>T p.R134W 7:101223799-101223799 9
6 COSM50818 ZNF813 large intestine,colon,carcinoma,NS c.1636G>A p.G546R 19:53491871-53491871 9
7 COSM50465 ZNF536 large intestine,colon,carcinoma,NS c.1158G>T p.W386C 19:30444720-30444720 9
8 COSM50466 ZNF536 large intestine,colon,carcinoma,NS c.2533C>G p.L845V 19:30548152-30548152 9
9 COSM50281 ZNF521 large intestine,colon,carcinoma,NS c.3524C>T p.T1175M 18:25224394-25224394 9
10 COSM50969 ZNF280D large intestine,colon,carcinoma,NS c.2020A>C p.R674R 15:56658461-56658461 9
11 COSM32994 ZNF217 large intestine,colon,carcinoma,NS c.967G>A p.D323N 20:53581860-53581860 9
12 COSM32679 ZNF155 large intestine,colon,carcinoma,NS c.1421A>G p.H474R 19:43997278-43997278 9
13 COSM50671 ZMIZ2 large intestine,colon,carcinoma,NS c.1850G>A p.R617H 7:44763403-44763403 9
14 COSM50764 ZFHX4 large intestine,colon,carcinoma,NS c.681C>A p.F227L 8:76704769-76704769 9
15 COSM6964399 ZFHX3 large intestine,colon,carcinoma,NS c.2339C>T p.A780V 16:72957807-72957807 9
16 COSM6944275 ZFHX3 large intestine,colon,carcinoma,NS c.2324C>T p.A775V 16:72957822-72957822 9
17 COSM6957094 ZFHX3 large intestine,colon,carcinoma,NS c.3412A>T p.I1138F 16:72889767-72889767 9
18 COSM6953704 ZFHX3 large intestine,colon,carcinoma,NS c.1623G>C p.Q541H 16:72958523-72958523 9
19 COSM6845173 ZFHX3 large intestine,colon,carcinoma,NS c.3863C>T p.T1288M 16:72811578-72811578 9
20 COSM973505 ZFHX3 large intestine,colon,carcinoma,NS c.7928G>A p.R2643H 16:72794754-72794754 9
21 COSM6964664 ZFHX3 large intestine,colon,carcinoma,NS c.2318C>T p.A773V 16:72957828-72957828 9
22 COSM6939325 ZFHX3 large intestine,colon,carcinoma,NS c.9997C>A p.Q3333K 16:72788279-72788279 9
23 COSM6845177 ZFHX3 large intestine,colon,carcinoma,NS c.7490C>T p.S2497L 16:72795192-72795192 9
24 COSM6941798 ZFHX3 large intestine,colon,carcinoma,NS c.10754C>G p.S3585C 16:72787522-72787522 9
25 COSM6941382 ZFHX3 large intestine,colon,carcinoma,NS c.392G>T p.G131V 16:72959754-72959754 9
26 COSM6964606 ZFHX3 large intestine,colon,carcinoma,NS c.5555A>C p.Q1852P 16:72797127-72797127 9
27 COSM6939326 ZFHX3 large intestine,colon,carcinoma,NS c.4242A>C p.E1414D 16:72798440-72798440 9
28 COSM6964400 ZFHX3 large intestine,colon,carcinoma,NS c.500C>T p.P167L 16:72959646-72959646 9
29 COSM6941989 ZFHX3 large intestine,colon,carcinoma,NS c.4251G>C p.Q1417H 16:72798431-72798431 9
30 COSM6941490 ZFHX3 large intestine,colon,carcinoma,NS c.10415C>T p.A3472V 16:72787861-72787861 9
31 COSM6955210 ZFHX3 large intestine,colon,carcinoma,NS c.7381G>A p.E2461K 16:72795301-72795301 9
32 COSM4062694 ZFHX3 large intestine,colon,carcinoma,NS c.10346C>T p.A3449V 16:72787930-72787930 9
33 COSM6955208 ZFHX3 large intestine,colon,carcinoma,NS c.7804A>G p.T2602A 16:72794878-72794878 9
34 COSM6942790 ZFHX3 large intestine,colon,carcinoma,NS c.1532C>A p.P511H 16:72958614-72958614 9
35 COSM6977044 ZFHX3 large intestine,colon,carcinoma,NS c.3367C>T p.R1123W 16:72889812-72889812 9
36 COSM6956224 ZFHX3 large intestine,colon,carcinoma,NS c.950T>A p.L317H 16:72959196-72959196 9
37 COSM6941990 ZFHX3 large intestine,colon,carcinoma,NS c.1081G>A p.G361R 16:72959065-72959065 9
38 COSM6978946 ZFHX3 large intestine,colon,carcinoma,NS c.9227T>G p.M3076R 16:72793455-72793455 9
39 COSM6927022 ZFHX3 large intestine,colon,carcinoma,NS c.2822C>T p.S941L 16:72950863-72950863 9
40 COSM6959968 ZFHX3 large intestine,colon,carcinoma,NS c.2548C>A p.L850I 16:72957598-72957598 9
41 COSM6950051 ZFHX3 large intestine,colon,carcinoma,NS c.1238C>A p.T413N 16:72958908-72958908 9
42 COSM4062703 ZFHX3 large intestine,colon,carcinoma,NS c.8968G>A p.V2990I 16:72793714-72793714 9
43 COSM6974762 ZFHX3 large intestine,colon,carcinoma,NS c.9467G>A p.S3156N 16:72788809-72788809 9
44 COSM3276831 ZFHX3 large intestine,colon,carcinoma,NS c.6296C>T p.P2099L 16:72796386-72796386 9
45 COSM6845159 ZFHX3 large intestine,colon,carcinoma,NS c.3829G>A p.V1277M 16:72811612-72811612 9
46 COSM6955209 ZFHX3 large intestine,colon,carcinoma,NS c.7666G>A p.A2556T 16:72795016-72795016 9
47 COSM33074 ZEB2 large intestine,colon,carcinoma,NS c.2947G>A p.D983N 2:144396532-144396532 9
48 COSM32424 ZDHHC7 large intestine,colon,carcinoma,NS c.130G>A p.D44N 16:84990489-84990489 9
49 COSM32851 ZBTB46 large intestine,colon,carcinoma,NS c.25G>T p.E9* 20:63790733-63790733 9
50 COSM33142 YIPF1 large intestine,colon,carcinoma,NS c.475C>T p.R159* 1:53871378-53871378 9

Expression for Colon Adenocarcinoma

Search GEO for disease gene expression data for Colon Adenocarcinoma.

Pathways for Colon Adenocarcinoma

Pathways related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.61 APC BAX CASP3 CDH1 CTNNB1 MLH1
2 12.53 APC BAX CASP3 CDH1 CTNNB1 MLH1
3
Show member pathways
12.51 APC BAX CASP3 CDH1 CTNNB1 PTGS2
4
Show member pathways
12.47 ABCB1 APC BAX CDH1 CTNNB1 MLH1
5 12.42 ABCB1 APC CASP3 PTGS2
6 12.41 MLH1 MSH6 RAD54L TYMS
7 12.33 APC CDH1 CTNNB1 PTGS2
8 11.98 APC CASP3 CDH1 CTNNB1
9 11.9 CDH1 CEACAM5 CTNNB1 CTNND1
10
Show member pathways
11.84 APC CASP3 CDH1 CTNNB1
11 11.77 BAX CASP3 PTGS2
12
Show member pathways
11.76 CDH1 CTNNB1 CTNND1
13 11.69 BAX CASP3 CDH1 CTNNB1 MSH6 ODC1
14 11.68 APC CDH1 CTNNB1
15 11.62 CDH1 CTNNB1 CTNND1
16 11.53 BAX CASP3 MLH1 MSH6
17 11.52 CASP3 CTNNB1 PTGS2
18 11.44 APC BAX CASP3 CDH1 CTNNB1 MLH1
19 11.41 BAX CASP3 MSH6
20 11.39 CDH1 CTNNB1 CTNND1
21 11.34 CDH1 CTNNB1 CTNND1
22
Show member pathways
11.33 ABCB1 MLH1 NQO1
23 11.31 CDH1 CTNNB1 CTNND1
24 11.19 CDH1 CTNNB1 CTNND1
25 11.1 MLH1 MSH6 NQO1
26 10.97 ABCB1 BAX CASP3
27 10.81 ABCB1 PTGS2
28 10.73 CDH1 CTNNB1
29 10.6 ABCB1 BAX

GO Terms for Colon Adenocarcinoma

Cellular components related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 postsynaptic density, intracellular component GO:0099092 9.48 CTNNB1 CTNND1
2 presynaptic active zone cytoplasmic component GO:0098831 9.46 CTNNB1 CTNND1
3 lamellipodium GO:0030027 9.46 APC CDH1 CTNNB1 CTNND1
4 mismatch repair complex GO:0032300 9.43 MLH1 MSH6
5 lateral plasma membrane GO:0016328 9.43 APC CDH1 CTNNB1
6 beta-catenin destruction complex GO:0030877 9.4 APC CTNNB1
7 Wnt signalosome GO:1990909 9.37 APC CTNNB1
8 flotillin complex GO:0016600 9.32 CDH1 CTNNB1
9 cell-cell adherens junction GO:0005913 9.26 APC CDH1 CTNNB1 CTNND1
10 catenin complex GO:0016342 8.92 APC CDH1 CTNNB1 CTNND1

Biological processes related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 CASP3 CEACAM5 CTNNB1 NQO1 PTGS2
2 positive regulation of apoptotic process GO:0043065 9.88 APC BAX CASP3 CTNNB1 PTGS2
3 cellular response to DNA damage stimulus GO:0006974 9.8 APC BAX CASP3 MLH1 MSH6 RAD54L
4 response to organic substance GO:0010033 9.72 CASP3 CDH1 PTGS2
5 response to glucocorticoid GO:0051384 9.71 CASP3 PTGS2 TYMS
6 response to organic cyclic compound GO:0014070 9.71 CASP3 NQO1 PTGS2 TYMS
7 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.69 BAX MLH1 MSH6
8 response to estradiol GO:0032355 9.67 CASP3 CTNNB1 NQO1 PTGS2
9 adherens junction organization GO:0034332 9.63 CDH1 CTNNB1 CTNND1
10 somatic hypermutation of immunoglobulin genes GO:0016446 9.58 MLH1 MSH6
11 isotype switching GO:0045190 9.58 MLH1 MSH6
12 determination of adult lifespan GO:0008340 9.56 MSH6 RAD54L
13 response to toxic substance GO:0009636 9.56 BAX CDH1 NQO1 TYMS
14 regulation of cellular amino acid metabolic process GO:0006521 9.52 NQO1 ODC1
15 cellular response to indole-3-methanol GO:0071681 9.49 CDH1 CTNNB1
16 positive regulation of neuron apoptotic process GO:0043525 9.46 BAX CASP3 CTNNB1 NQO1
17 somatic recombination of immunoglobulin gene segments GO:0016447 9.43 MLH1 MSH6
18 response to drug GO:0042493 9.17 ABCB1 CASP3 CDH1 CTNNB1 PTGS2 RAD54L
19 entry of bacterium into host cell GO:0035635 9.13 CDH1 CTNNB1 CTNND1

Molecular functions related to Colon Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cadherin binding GO:0045296 9.62 APC CDH1 CTNNB1 CTNND1
2 gamma-catenin binding GO:0045295 9.26 APC CDH1
3 protein homodimerization activity GO:0042803 9.17 BAX CDH1 CEACAM5 MSH6 ODC1 PTGS2
4 mismatched DNA binding GO:0030983 9.16 MLH1 MSH6
5 guanine/thymine mispair binding GO:0032137 8.96 MLH1 MSH6

Sources for Colon Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....